Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2+ Metastatic Breast Cancer × asciminib × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18 Leukemia, Myeloid, Chronic-Phase 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Philadelphia Chromosome 2 Myeloproliferative Disorders 2 Leukemia, Myeloid 2 Leukemia 2 Bronchiolitis Obliterans Syndrome 2 Malignant Solid Tumors 1 Hematologic Diseases 1 HER2+ Metastatic Breast Cancer 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Blast Crisis 1

Interventions

asciminib 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07136428 2025-12-19

ASCENdANT

Duke University

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡